Biologics Fill / Finish Services Market (2nd Edition) by Type of Primary Packaging Container (Ampoules, Cartridges, Syringes and Vials), Type of Biologic (Antibodies, Cell Therapy, Gene Therapy, Oligonucleotides, Recombinant Proteins, Vaccines and Others

Biologics Fill / Finish Services Market (2nd Edition) by Type of Primary Packaging Container (Ampoules, Cartridges, Syringes and Vials), Type of Biologic (Antibodies, Cell Therapy, Gene Therapy, Oligonucleotides, Recombinant Proteins, Vaccines and Others), Scale of Operation (Preclinical / Clinical and Commercial), Key Therapeutic Areas, Geographical Regions (North America, Europe, Asia Pacific, MENA and Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

Product Title: Biologics Fill / Finish Services Market (2nd Edition) by Type of Primary Packaging Container (Ampoules, Cartridges, Syringes and Vials), Type of Biologic (Antibodies, Cell Therapy, Gene Therapy, Oligonucleotides, Recombinant Proteins, Vaccines and Others), Scale of Operation (Preclinical / Clinical and Commercial), Key Therapeutic Areas, Geographical Regions (North America, Europe, Asia Pacific, MENA and Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030
Product Code: RA100271
Publication Date: 6 May 2021
Number of Pages: 539
Number of Figures: 246
Number of Tables: 268

INTRODUCTION

Over the last few decades, as a consequence of the therapeutic efficacy and favorable safety profiles of various marketed candidates and those under development, the biopharmaceutical industry has witnessed tremendous growth. The overwhelming success of this upcoming class of products has prompted both established and novice pharmaceutical innovators to develop assets in this arena. Currently, there are close to 400 approved products and more than 4,000 biologic candidates in clinical trials, being developed for the treatment of a wide variety of diseases. , As the number of commercialized products and clinical stage therapy candidates increases, the demand for adequate manufacturing capacities and affiliated capabilities is also on the rise. In the production cycle, the (aseptic) fill / finish process is a crucial step. Biopharmaceutical fill / finish operations are relatively more complicated, involving sterilization of all affiliated components before use, filling in a sterile environment, and the use of appropriate post filling sterilization methods. Even minute errors during the aforementioned step can have catastrophic consequences, resulting in heavy losses for the innovator company. Therefore, it is important for companies to establish fill / finish related expertise and build / maintain the necessary infrastructure.

To meet some the abovementioned challenges, drug developers have not hesitated to outsource fill / finish operations to capable contract service providers. Currently, around 170 companies claim to be actively providing fill / finish services for biologics. As is generally the trend among service providers, stakeholders in this domain are making active attempts to adopt the latest technological innovations, in order to meet the growing demand for fill / finish services, reduce cost of operation / increase efficiency, and comply to evolving safety and regulatory requirements, and thereby, differentiate themselves amidst the competition. Over the last few years, the fill / finish services industry has witnessed more than 120 instances of expansion, most of which were intended to increase capacity. We believe that the companies involved this segment of the industry are likely to continue to undertake similar initiatives to cater to the growing needs of their clientele. In addition, significant partnership activity between sponsors and services providers has also been reported in the recent past; a substantial number of deals were observed to have been inked between vaccine developers and CMOs, focused on the fulfilment of fill / finish requirements for multiple vaccines against COVID-19. Considering the anticipated growth in the biologics market, the corresponding opportunity for fill / finish service providers is expected to grow at a steady pace over the coming years.


The “Biologics Fill / Finish Services Market (2nd Edition) by Type of Primary Packaging Container (Ampoules, Cartridges, Syringes and Vials), Type of Biologic (Antibodies, Cell Therapy, Gene Therapy, Oligonucleotides, Recombinant Proteins, Vaccines and Others), Scale of Operation (Preclinical / Clinical and Commercial), Key Therapeutic Areas, Geographical Regions (North America, Europe, Asia Pacific, MENA and Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study on the biologics fill / finish service providers. The study features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:
 A detailed review of the overall landscape of the companies offering fill / finish services for biopharmaceuticals / biologics, along with analyses based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill / finish facilities, types of packaging form (ampoules, cartridges, syringes and vials), type of biologic filled (ADC, antibodies, biosimilars, cell therapies, gene therapies, oligonucleotides, peptides / proteins, vaccines, viral products, and others), scale of operation (preclinical, clinical and commercial), type of additional services offered (lyophilization, labelling, quality testing, storage and distribution services) and including details on fill / finish capacity and fill volume range.
 A detailed competitiveness analysis of the fill / finish service providers based in different geographies offering services across various packaging types, based on supplier strength (in terms of experience and company size), service strength (in terms of number of fill / finish facilities, geographical reach and scale of operation) and types of biologics handled.
 Elaborate profiles of key players based in North America, Europe and Asia-Pacific. Each profile provides an overview of the company, information on its service offerings, fill / finish facilities, financial information (if available), details on partnerships, expansions and recent awards and accolades, and an informed future outlook.
 An analysis of the partnerships and collaborations focused on the fill / finish operations of biologic drug products, which were established since 2013, based on year of agreement, type of agreement, scale of operation, types of services mentioned in the deal, types of biologics involved and location of fill / finish facilities involved.
 A review of the recent expansions (since 2015) undertaken by biologics fill / finish service providers, including a detailed analysis based on various parameters, such as year of expansion, type of expansion (capacity expansion and new facility), type of packaging form, types of services offered, types of biologics involved, scale of operation (preclinical, clinical and commercial), the most active players and geographical location of the added facility.
 An estimate of the global fill / finish capacity for filling of biologics, by taking into consideration the capacities of various fill / finish service providers. The fill / finish capacity has been analyzed in terms of number of units and volume of biologics filled, across various type of packaging containers (ampoules, cartridges, syringes, and vials), for the service providers distributed on the basis of company size (small, mid-sized and large) and geographical location (North America, Europe and Asia Pacific).
 An informed estimate of the annual demand for fill / finish of the top 25 biologics, based on various relevant parameters, such as target patient population, dosing frequency, dose strength, type of packaging container and volume of the packaging container of these products.
 A regional capability assessment framework, which compares the fill / finish capabiility across key geographies, based on a number of parameters, such as the number of biologic fill / finish service providers, number of biologic fill / finish facilities, number of biologic fill / finish partnerships inked in that particular geographical region, number of facility expansions and installed biologic fill / finish capacity in that particular geographical region.
 An analysis to identify the key performance indicators for service providers engaged in this domain, based on information gathered via secondary research and primary research.
 A case study to highlight the benefits of using robotic / automated equipment for aseptic fill / finish processes, providing a list of equipment manufacturers providing robots suitable for pharmaceutical operations.
 A case study to highlight the role of ready-to-use packaging containers in aseptic fill / finish operations, providing a list of suppliers providing the ready-to-use components.
 A discussion on the potential growth areas, such as growing biopharmaceutical pipeline, increasing outsourcing of fill / finish operations, rising focus on self-administration enabling drug delivery devices and growing opportunities in the Asia-Pacific region.

One of the key objectives of this report was to estimate the current market size and the future opportunity in the biologics fill / finish services market, over the coming decade. Based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, direct manufacturing costs, share of drug product manufacturing costs and outsourcing trends related to fill / finish operations, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. In order to provide a detailed future outlook, year-wise projections of the current and future opportunity have been further segmented on the basis of [A] types of packaging containers used for fill / finish (ampoules, cartridges, syringes and vials), [B] scale of operation (preclinical, clinical and commercial), [C] types of biologics (antibodies, cell therapy, gene therapy, oligonucleotides, recombinant proteins, vaccines and others), [D] key therapeutic areas (autoimmune disorders, cardiovascular disorders, infectious disorders, oncological disorders and other disorders), and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia-Pacific (Japan, China, South Korea, India and Australia), MENA, Latin America and Rest of the World). To account for the uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. The perceptions presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:
 Gregor Kawaletz (Chief Commercial Officer, IDT Biologika)
 Matt Delaney (Vice President Business Development & Marketing, ‎Cytovance Biologics)
 Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International)
 Ales Sima (Business Development Manager, Oncomed Manufacturing)
 Amit Chandra (Technology Watch Manager, Yposkesi)
 Jos Vergeest (International Business Developer, HALIX)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

1.1. KEY QUESTIONS ANSWERED
 Who are the leading contract service providers with expertise in fill / finish services for biologics?
 In which regions are majority of the biologic fill / finish facilities located?
 What percentage of ampoules, cartridges, vials and syringes are filled annually with biologics?
 Which partnership models are most commonly adopted by stakeholders in this industry?
 What type of expansion initiatives are being carried out by players in this domain?
 What is the current, global demand for biologic fill / finish services?
 How is the current and future market opportunity likely to be distributed across key market segments?

1.2. RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily beneficial for us to draw opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been laid on forecasting the market over the time period 2021-2030, the report also provides our independent views on various technological and non-commercial trends emerging in the industry. The opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources.

1.3. CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the biologics fill / finish service providers market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to biopharmaceuticals and contract manufacturing. The chapter features a detailed discussion on the need for outsourcing within the biopharmaceutical industry and highlights the key operations outsourced by the biologic drug developers, including fill / finish. Additionally, the chapter highlights the key considerations for selecting a fill / finish service provider, along with the benefits and risks associated with outsourcing fill / finish operations.

Chapter 4 provides an overview of the overall biologics fill / finish contract services landscape. It includes information on close to 170 contract service providers currently engaged in this domain. Additionally, it features an in-depth analysis of service providers, based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill / finish facilities, types of packaging form (ampoules, cartridges, syringes and vials), type of biologic filled (ADC, antibodies, biosimilars, cell therapies, gene therapies, oligonucleotides, peptides / proteins, vaccines, viral products, and others), scale of operation (preclinical, clinical and commercial), type of additional services offered (lyophilization, labelling, quality testing, storage and distribution services) and including details on fill / finish capacity and fill volume range.

Chapter 5 features a detailed competitiveness analysis of the service providers based in North America, Europe and Asia-Pacific. The companies within each geography have been compared on the basis of the type of packaging used for fill / finish services, supplier strength (considering experience and company size of service provider), service strength (considering number of fill / finish facilities, geographical reach, number of additional services offered and highest scale of operation) and type of biologics involved.

Chapter 6 includes detailed profiles of the key players in the biopharmaceutical fill / finish contract services market in North America. Each profile features a brief overview of the company, its overall contract service offerings highlighting the capabilities of fill / finish facilities (if available), financial information (if available), recent developments and an informed future outlook.

Chapter 7 includes detailed profiles of the key players in the biopharmaceutical fill / finish contract services market in Europe. Each profile features a brief overview of the company, its overall contract service offerings highlighting the capabilities of fill / finish facilities (if available), financial information (if available), recent developments and an informed future outlook.

Chapter 8 includes detailed profiles of the key players in the biopharmaceutical fill / finish contract services market in Asia-Pacific. Each profile features a brief overview of the company, its overall contract service offerings highlighting the capabilities of fill / finish facilities (if available), financial information (if available), recent developments and an informed future outlook.

Chapter 9 features a detailed analysis of the various collaborations and partnerships that have been inked amongst players since 2013. It includes a brief description of the partnership models (including acquisition, supply agreement, service alliance, merger and joint venture) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of agreement, the scale of operation of the project, focus area, types of services provided, types of biologics and location of the facilities where the project is to be executed.

Chapter 10 presents a detailed analysis of the expansions undertaken by various service providers to enhance fill / finish capabilities, based on various parameters, including year of expansion, type of expansion, geographical location of the facility, type of packaging container involved, scale of operation (as mentioned in the expansion terms), types of services offered, types of biologics filled, and expansion details (in terms of new area added to the existing facilities). It also highlights the most active players (in terms of number of instances) in the domain.

Chapter 11 features a comprehensive analysis of the global fill / finish capacity, by taking into consideration the container processing capacities of various fill / finish service providers (as available on respective company websites). The global biopharmaceutical fill / finish capacity has been distributed across number of packaging units, type of packaging container (ampoules, cartridges, syringes and vials), company size of the manufacturer (small, mid-sized and large) and geographical location (North America, Europe and Asia-Pacific).

Chapter 12 provides an estimate of the annual demand for fill / finish of top 25 biologics (in number of units of packaging containers), based on various relevant parameters, such as target patient population, dosing frequency, dose strength, type of packaging container and volume of the packaging container of the abovementioned products.

Chapter 13 features an analysis on the key performance indicators of service providers based on information available for top-ten biopharmaceutical players on various public platforms, as well as inputs obtained from primary research.

Chapter 14 presents a regional capability assessment framework, which compares the fill / finish capability across key geographies, based on a number of parameters, such as the number of biologics fill / finish service providers, number of biologics fill / finish facilities, number of biologics fill / finish partnerships inked in that particular geographical region, number of facility expansions and installed biologics fill / finish capacity in that particular geographical region.

Chapter 15 presents a comprehensive market forecast analysis, highlighting the likely growth of the biologics’ fill / finish services market till the year 2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] types of primary packaging containers used for fill / finish (ampoules, cartridges, syringes and vials), [B] scale of operation (preclinical, clinical and commercial), [C] types of biologics filled (antibodies, cell therapy, gene therapy, oligonucleotides, recombinant proteins, vaccines and others), [D] key therapeutic areas (cancer, infectious diseases, autoimmune diseases, cardiovascular diseases and other indications, and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia (Japan, China, South Korea and India), MENA and Latin America and Rest of the World).

Chapter 16 includes a discussion on the various potential growth drivers for the biologics fill / finish services market, which takes into account the opportunities associated with the growing biopharmaceutical pipeline, increase in outsourcing of fill / finish operations, rising focus on self-administration of drugs / therapies and opportunities in the Asia-Pacific region.

Chapter 17 is a case study focused on use of robotic systems in fill / finish operations. It provides a list of equipment used by the service providers (wherever specified) for fill / finish operations, highlighting the purpose of robotics in various manufacturing operations. It also includes a list of companies providing robots for use in manufacturing processes carried in the pharmaceutical sector.

Chapter 18 is a case study on the use of ready-to-use packaging components in the aseptic fill / finish operations. It also provides a list of suppliers providing ready-to-use components.

Chapter 19 is a summary of the overall report wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the biologics fill / finish services market.

Chapter 20 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical contract manufacturing and fill / finish domain. In this study, we spoke to Gregor Kawaletz (Chief Commercial Officer, IDT Biologika), Matt Delaney (Vice President Business Development & Marketing, ‎Cytovance Biologics), Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International), Ales Sima (Business Development Manager, oncomed manufacturing), Amit Chandra (Technology Watch Manager, Yposkesi) and Jos Vergeest (International Business Developer, HALIX).

Chapter 21 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

LIST OF COMPANIES

1. 3P Biopharmaceuticals
2. Aalto Scientific
3. ABB
4. AbbVie
5. AbbVie Contract Manufacturing
6. Abzena
7. ACG
8. ACIC Pharmaceutical Machinery
9. AdaptVac
10. ADC Biotechnology
11. Adimmune
12. Advanced BioScience Laboratories
13. Affinity Life Sciences
14. Afton Scientific
15. Agilis Biotherapeutics
16. AJ Biologics
17. Ajinomoto Bio-Pharma Services
18. Akron Biotech
19. AKSO
20. Akums Drugs and Pharmaceuticals
21. Alanza
22. Alcami
23. Alcon
24. Aldevron
25. Alkermes
26. Althea
27. Althea Technologies
28. Amatsigroup
29. Ambica Pharma Machines
30. Amgen
31. Amicus Therapeutics
32. AMRI
33. Anchiano Therapeutics
34. Anchor Mark
35. Anthos Therapeutics
36. apceth Biopharma
37. APG Europe
38. Aptar Pharma
39. Aptuit
40. Arabio
41. ARaymond Life
42. Arch Biopartners
43. ARISTO
44. Aseptic Technologies
45. Asklepios BioPharmaceutical
46. AST
47. AstraZeneca
48. Asymchem
49. Ausia BioTech
50. Austrianova
51. Automated Systems of Tacoma
52. Avrio Biopharmaceuticals
53. AWS Bio-Pharma Technologies
54. Axcellerate Pharma
55. Baccinex
56. Bausch & Ströbel
57. BAUSCH Advanced Technology Group (BATG)
58. Bayer
59. Berkshire Sterile Manufacturing
60. Binex
61. Bio Elpida
62. Bio-Concept Laboratories
63. BioConnection
64. Biofabri
65. Biogen
66. BioMARC
67. Biomay
68. Biomedical Advanced Research and Development Authority (BARDA)
69. BioNTech IMFS
70. BioPharma Solutions
71. BioReliance
72. BioTechLogic
73. BioTechnique
74. BioTechniques
75. Biovian
76. BirgiMefar
77. Boehringer Ingelheim BioXcellence
78. Bolt Biotherapeutics
79. Boston Children’s Hospital
80. Bristol-Myers Squibb
81. Bryllan
82. BSP Pharmaceuticals
83. Burrard Pharmaceuticals
84. Cangene Corporation
85. Canton Biologics
86. CARBOGEN AMCIS
87. Catalent Biologics
88. Celgene
89. Cell Culture Company
90. Cellin Technologies
91. Celonic
92. Cenexi
93. Cerbios-Pharma
94. Cerium Pharmaceuticals
95. ChemPartner
96. Chime Biologics
97. China Gateway Biologics
98. CinnaGen
99. Citryll
100. CMAB Biopharma
101. CMC Biologics
102. Coalition for the Promotion of Innovations for Epidemic Preparedness (CEPI)
103. Cobra Biologics
104. Cognate BioServices
105. Coldstream Laboratories
106. Colorado State University
107. Columbus Venture Partners
108. Comecer
109. Cook Pharmica
110. CordenPharma
111. Creative Biolabs
112. Crystal Pharma
113. CureVac
114. CytoDyn
115. Cytovance Biologics
116. Daikyo Seiko
117. Dalton Pharma Services
118. Dara Pharma
119. Datwyler Sealing Solutions
120. DENSO
121. Dhruv Life Sciences
122. Disposable Lab
123. DM Bio
124. DSM Pharmaceutical Products
125. DWK Life Sciences
126. EirGen Pharma
127. EirGenix
128. Eli Lilly
129. EMA Pharmaceuticals
130. Emcure Pharmaceuticals
131. Emergent BioSolutions
132. Esco Aster
133. Etinpro
134. EuBiologics
135. EUCODIS Bioscience
136. Eurofins BioPharma Product Testing Netherlands
137. Eurofins Scientific
138. EVER Pharma
139. Exelead
140. Experic
141. Extract Technology
142. FANUC America
143. Fareva
144. FinVector
145. Formosa Laboratories
146. Fresenius Kabi Contract Manufacturing
147. FUJIFILM Diosynth Biotechnologies
148. GC Pharma
149. GEA
150. Genentech
151. GeneQuantum Healthcare
152. Generic Specialities
153. GenIbet Biopharmaceuticals
154. Genovior Biotech
155. Genprex
156. Gerresheimer
157. Getinge
158. GigaGen
159. Gilead
160. GlaxoSmithKline
161. GLyPharma
162. Goodwin Biotechnology
163. GP Pharm
164. Grand River Aseptic Manufacturing
165. Groninger
166. GTCR
167. Gulf Biotech
168. HALIX
169. Hameln Pharma
170. Handl Therapeutics
171. Hansa Biopharma
172. Hapten Sciences
173. Health Biotech
174. Healthcare Pharmaceuticals
175. Hepalink
176. Hetero Drugs
177. Hisun Pharmaceuticals USA
178. Hookipa Pharma
179. Hospira One 2 One
180. Humanigen
181. Hybio Pharmaceutical
182. Hycult Biotech
183. IDT Biologika
184. IMA Group
185. Immune Pharmaceuticals
186. Immunex
187. Infectious Disease Research Institute
188. Injectalia
189. Intas Pharmaceuticals
190. Integrity Bio
191. Irvine Pharmaceutical Services
192. Istituto Biochimico Italiano Giovanni Lorenzini
193. Janssen Pharmaceuticals
194. JHL Biotech
195. Johnson & Johnson
196. JOINN Biologics
197. Jubilant HollisterStier
198. Kanda BioTech
199. Kaneka Eurogentec
200. Kawasaki Heavy Industries
201. Kaysersberg Pharmaceuticals
202. Kemwell Biopharma
203. Klenzaids
204. Kohlberg and Mubadala
205. KUKA
206. Laboratorios Farmaceuticos ROVI
207. Laekna Therapeutics
208. LamKap Bio
209. Lava Therapeutics
210. Liof Pharma
211. Lonza
212. LSNE Contract Manufacturing
213. Lubrizol
214. LuinaBio
215. Lyophilization Technology
216. M&O Perry Industries
217. MabPlex
218. Madison Dearborn Partners
219. Marchesini Group
220. MassBiologics
221. Massman Automation Designs
222. MaSTherCell
223. MEDInstill
224. Merck
225. Microdermics
226. Millmount Healthcare (acquired by PCI Pharma Services)
227. Miltenyi Biotec
228. Minaris Regenerative Medicine
229. Mitsubishi Electric
230. Moderna
231. Mycenax Biotech
232. Najít Technologies
233. National Institutes of Health
234. NBE-Therapeutics
235. Nikon CeLL innovation
236. Ningbo Zhengli Pharmaceutical Packing
237. Nipro PharmaPackaging
238. Nitto Avecia Pharma Services
239. Nitto Denko Avecia
240. Northway Biotechpharma
241. Nova Laboratories
242. Novartis
243. Novasep
244. Noveome Biotherapeutics
245. Novex Innovations
246. Novo Nordisk
247. Ology Bioservices
248. OmniChem
249. Ompi
250. OMRON Industrial Automation
251. oncomed manufacturing
252. Oncotec Pharma Produktion
253. OPKO Health
254. OPTIMA
255. Oryn Therapeutics
256. OSO Biopharmaceuticals Manufacturing (acquired by AMRI)
257. Ottawa Hospital Research Institute
258. Oxford BioMedica
259. Pace Analytical
260. PaizaBio
261. Pall Life Sciences
262. Panacea Pharmaceuticals
263. Paragon Bioservices
264. Particle Measuring Systems
265. Partners Group
266. Patheon
267. PCI Pharma Services
268. Penn Pharmaceutical Services
269. Permira
270. Pfizer
271. Pfizer CentreOne
272. Pharmaceutical Packaging Professionals
273. Pierre Fabre
274. Piramal Pharma Solutions
275. Polpharma Biologics
276. Polymun Scientific
277. Praxis Pharmaceutical
278. PrimaPharma
279. Prince Sterilization Services
280. PSC Biotech
281. PYRAMID Laboratories
282. Quality BioResources
283. QureBio
284. Recipharm
285. Regeneron Pharmaceuticals
286. Reliance Life Sciences
287. Rentschler Biopharma
288. Rentschler Fill Solutions
289. Revance Therapeutics
290. Roche
291. Romaco
292. Rommelag CMO
293. RoslinCT
294. ROTA
295. Ruibo Bio-Technology
296. Russian Direct Investment Fund (RDIF)
297. Samsung Bioepis
298. Samsung Biologics
299. Sandoz
300. Sanofi
301. Saudi Biotechnology Manufacturing
302. Schematic Engineering Industries
303. SCHOTT
304. ScinoPharm
305. Seiko Epson
306. Selecta Biosciences
307. Sensorion
308. Shengnuo Peptide
309. Sherpa Clinical Packaging Packaging (acquired by PCI Pharma Services)
310. Shibuya
311. Shree Bhagwati Machtech (India)
312. SialoCarb
313. Siam Bioscience
314. Siegfried Holding
315. Singota Solutions
316. Sio Gene Therapies
317. SiO2 Medical Products
318. SIRION Biotech
319. Sirton Pharmaceuticals
320. SKAN
321. Snowbell Machines
322. SP
323. Square Pharmaceuticals
324. Staubli
325. Steriline
326. Surrozen
327. Swissfillon
328. Symbiosis Pharmaceutical
329. Symphogen
330. SynCo Bio Partners
331. Syngene
332. Synklino
333. Syntegon
334. Sypharma
335. National Health Research Institutes (NHRI)
336. Takara Bio
337. Tanvex BioPharma
338. Taysha Gene Therapies
339. Tekpak
340. The Carlyle Group
341. Therapure Biomanufacturing
342. Thermo Fisher Scientific
343. Tofflon
344. Transcoject
345. TriPharm Services (acquired by Alcami)
346. TRUKING
347. Tubulis
348. U.S. Army Contracting Command
349. UCB
350. Ultragenyx Pharmaceutical
351. Universal Robots
352. University of Queensland
353. USV
354. Vanrx
355. Vaxine
356. VBI Vaccines
357. Vetter Pharma
358. VGXI
359. Vibalogics
360. Vaccine and Infectious Disease Organization (VIDO)
361. Vigene Biosciences
362. Viralgen
363. VxP Biologics
364. WACKER Biotech
365. Waisman Biomanufacturing
366. Watson-Marlow Fund
367. West Pharmaceutical Services
368. WuXi Biologics
369. Wuxi Fortune Pharmaceutical
370. Wuxi Griffin
371. Yaskawa Electric
372. Yposkesi

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Biologics
3.3. Need for Outsourcing Biologics-related Operations
3.4. Introduction to Contract Manufacturing
3.5. Commonly Outsourced Operations in the Biopharmaceutical Industry
3.5.1. Biologics Fill / Finish Operations
3.6. Basic Guidelines for Selecting a Fill / Finish Service Provider
3.7. Advantages of Outsourcing Fill / Finish Operations
3.8. Risks and Challenges of Outsourcing Fill / Finish Operations
4. BIOLOGICS FILL / FINISH SERVICE PROVIDERS: COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Biologics Fill / Finish Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Fill / Finish Facilities
4.2.5. Analysis by Type of Packaging
4.2.6. Analysis by Type of Biologics Filled
4.2.7. Analysis by Scale of Operation
4.2.8. Analysis by Additional Services Offered
4.2.9. Information on Fill / Finish Capacity
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology and Key Parameters
5.3. Biologics Fill / Finish Service Providers in North America
5.4.1. Players Offering Services in Ampoules
5.4.2. Players Offering Services in Cartridges
5.4.3. Players Offering Services in Syringes
5.4.4. Players Offering Services in Vials
5.5. Biologics Fill / Finish Service Providers in Europe
5.5.1. Players Offering Services in Ampoules
5.5.2. Players Offering Services in Cartridges
5.5.3. Players Offering Services in Syringes
5.5.4. Players Offering Services in Vials
5.6. Biologics Fill / Finish Service Providers in Asia-Pacific and RoW
5.6.1. Players Offering Services in Ampoules
5.6.2. Players Offering Services in Cartridges
5.6.3. Players Offering Services in Syringes
5.6.4. Players Offering Services in Vials
6. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. AbbVie Contract Manufacturing
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Financial Information
6.2.4. Recent Developments and Future Outlook
6.3. BioPharma Solutions
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. BioReliance
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Financial Information
6.4.4. Recent Developments and Future Outlook
6.5. Catalent Biologics
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Financial Information
6.5.4. Recent Developments and Future Outlook
6.6. Patheon
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Financial Information
6.6.4. Recent Developments and Future Outlook
7. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN EUROPE
7.1. Chapter Overview
7.2. Boehringer Ingelheim BioXcellence
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Financial Information
7.2.4. Recent Developments and Future Outlook
7.3. Lonza
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3. Financial Information
7.3.4. Recent Developments and Future Outlook
7.4. Pierre Fabre
7.4.1. Company Overview
7.4.2. Service Portfolio
7.4.3. Financial Information
7.4.4. Recent Developments and Future Outlook
7.5. Recipharm
7.5.1. Company Overview
7.5.2. Service Portfolio
7.5.3. Financial Information
7.5.4. Recent Developments and Future Outlook
7.6. Wacker Biotech
7.6.1. Company Overview
7.6.2. Service Portfolio
7.6.3. Financial Information
7.6.4. Recent Developments and Future Outlook
8. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC
8.1. Chapter Overview
8.2. Asymchem
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Financial Information
8.2.4. Recent Developments and Future Outlook
8.3. Samsung Biologics
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Financial Information
8.3.4. Recent Developments and Future Outlook
8.4. Syngene
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. Financial Information
8.4.4. Recent Developments and Future Outlook
8.5. Takara Bio
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Financial Information
8.5.4. Recent Developments and Future Outlook
8.6. WuXi Biologics
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Financial Information
8.6.4. Recent Developments and Future Outlook
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Biologics Fill / Finish Service Providers: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Scale of Operation
9.3.4. Analysis by Type of Service
9.3.5. Analysis by Type of Process
9.3.6. Analysis by Type of Biologic Involved
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Geographical Analysis
9.3.8.1. Intercontinental and Intracontinental Agreements
9.3.8.2. Analysis by Geographical Location of Facilities
10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Biologics Fill / Finish Service Providers: Recent Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Type of Packaging Form
10.2.4. Analysis by Type of Service Offered
10.2.5. Analysis by Type of Biologic Involved
10.2.6. Analysis by Type of Biologic Involved and Scale of Operation
10.2.7. Most Active Players: Analysis by Type of Service
10.2.8. Geographical Analysis
10.2.9. Expansions in North America: Analysis by Type of Service Offered and Type of
Biologic Involved
10.2.10. Expansions in Europe: Analysis by Type of Service and Type of Biologic
10.2.11. Expansions in Asia-Pacific: Analysis by Type of Service and Type of Biologic
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Global Fill / Finish Capacity (by Number of Units Filled)
11.3.1. Analysis by Type of Packaging
11.3.2. Analysis by Company Size
11.3.3. Analysis by Scale of Operation
11.3.4. Analysis by Location of Headquarters
11.3.5. Analysis by Location of Fill / Finish Facilities
11.4. Global Fill / Finish Capacity (by Fill Volume)
11.4.1. Analysis by Type of Packaging
11.4.2. Analysis by Company Size
11.4.3. Analysis by Scale of Operation
11.4.4. Analysis by Location of Headquarters
11.4.5. Analysis by Location of Fill / Finish Facilities
11.5. Global Fill / Finish Capacity for Ampoules (by Number of Units Filled)
11.5.1 Analysis by Company Size
11.5.2 Analysis by Scale of Operation
11.5.3. Analysis by Location of Headquarters
11.5.4 Analysis by Location of Fill / Finish Facilities
11.6. Global Fill / Finish Capacity for Ampoules (by Fill Volume)
11.6.1. Analysis by Company Size
11.6.2. Analysis by Scale of Operation
11.6.3. Analysis by Location of Headquarters
11.6.4. Analysis by Location of Fill / Finish Facilities
11.7. Global Fill / Finish Capacity for Cartridges (by Number of Units Filled)
11.7.1. Analysis by Company Size
11.7.2. Analysis by Scale of Operation
11.7.3. Analysis by Location of Headquarters
11.7.4. Analysis by Location of Fill / Finish Facilities
11.8. Global Fill / Finish Capacity for Cartridges (by Fill Volume)
11.8.1. Analysis by Company Size
11.8.2. Analysis by Scale of Operation
11.8.3. Analysis by Location of Headquarters
11.8.4. Analysis by Location of Fill / Finish Facilities
11.9. Global Fill / Finish Capacity for Syringes (by Number of Units Filled)
11.9.1 Analysis by Company Size
11.9.2 Analysis by Scale of Operation
11.9.3. Analysis by Location of Headquarters
11.9.4 Analysis by Location of Fill / Finish Facilities
11.10. Global Fill / Finish Capacity for Syringes (by Fill Volume)
11.10.1. Analysis by Company Size
11.10.2. Analysis by Scale of Operation
11.10.3. Analysis by Location of Headquarters
11.10.4. Analysis by Location of Fill / Finish Facilities
11.11. Global Fill / Finish Capacity for Vials (by Number of Units Filled)
11.11.1 Analysis by Company Size
11.11.2 Analysis by Scale of Operation
11.11.3. Analysis by Location of Headquarters
11.11.4. Analysis by Location of Fill / Finish Facilities
11.12. Global Fill / Finish Capacity for Vials (by Fill Volume)
11.12.1. Analysis by Company Size
11.12.2. Analysis by Scale of Operation
11.12.3. Analysis by Location of Headquarters
11.12.4. Analysis by Location of Fill / Finish Facilities
11.13. Conclusion
12. DEMAND ANALYSIS
12.1. Chapter Overview
12.2. Assumptions and Methodology
12.3. Global Demand for Biologics Fill / Finish Services
12.3.1. Analysis by Type of Packaging
12.3.2. Analysis by Type of Biologic
12.3.3. Analysis by Therapeutic Area
12.3.4. Analysis by Geographical Location
12.4. Demand and Supply Analysis
13. KEY PERFORMANCE INDICATORS FOR BIOLOGIC MANUFACTURING AND FILL / FINISH
13.1. Chapter Overview
13.2. Biologics Manufacturing and Fill / Finish: Key Performance Indicators
13.2.1. Financial Indicators
13.2.1.1. Big Pharma Perspective
13.2.1.2. Contract Manufacturers’ Perspective
13.2.2. Process and Capability-related Indicators
13.2.2.1. Big Pharma Perspective
13.2.2.2. Contract Manufacturers’ Perspective
13.2.3. Market Reputation-related Indicators
13.2.3.1. Big Pharma Perspective
13.2.3.2. Contract Manufacturers’ Perspective
13.2.4. Other Important Performance Indicators
13.3.5. Conclusion
14. REGIONAL CAPABILITY ASSESSMENT
14.1. Chapter Overview
14.2. Assumptions and Key Parameters
14.3. Biologics Fill / Finish Capabilities in North America
14.4. Biologics Fill / Finish Capabilities in Europe
14.5. Biologics Fill / Finish Capabilities in Asia-Pacific Region
14.6. Concluding Remarks
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Forecast Methodology
15.3. Overall Biologics Fill / Finish Services Market, 2021-2030
15.3.1. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Packaging
15.3.2. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Scale of Operation
15.3.3. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Biologic
15.3.4. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Therapeutic Area
15.3.5. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Geographical Region
15.3.5.1 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Countries
15.3.5.2. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Packaging
15.3.5.3. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Scale of Operation
15.3.5.4. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Biologic
15.3.5.5. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Therapeutic Area
15.3.5.6. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Countries
15.3.5.7. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Packaging
15.3.5.8. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Scale of Operation
15.3.5.9. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Biologic
15.3.5.10. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Therapeutic Area
15.3.5.11. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Countries
15.3.5.12. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Packaging
15.3.5.13. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
15.3.5.14. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
15.3.5.15. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
15.4. Biologics Fill / Finish Services Market for Ampoules, 2021-2030
15.4.1. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Scale of Operation
15.4.2. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Type of Biologic
15.4.3. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Therapeutic Area
15.4.4. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Geographical Region
15.4.4.1. Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Scale of Operation
15.4.4.2. Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Type of Biologic
15.4.4.3. Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Therapeutic Area
15.4.4.4. Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Scale of Operation
15.4.4.5. Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Type of Biologic
15.4.4.6. Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Therapeutic Area
15.4.4.7. Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
15.4.4.8. Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
15.4.4.9. Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
15.5. Biologics Fill / Finish Services Market for Cartridges, 2021-2030
15.5.1. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Scale of Operation
15.5.2. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Type of Biologic
15.5.3. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Therapeutic Area
15.5.4. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Geographical Region
15.5.4.1. Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Scale of Operation
15.5.4.2. Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Type of Biologic
15.5.4.3. Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Therapeutic Area
15.5.4.4. Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Scale of Operation
15.5.4.5. Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Type of Biologic
15.5.4.6. Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Therapeutic Area
15.5.4.7. Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
15.5.4.8. Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
15.5.4.9. Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
15.6. Biologics Fill / Finish Services Market for Syringes, 2021-2030
15.6.1. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Scale of Operation
15.6.2. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Type of Biologic
15.6.3. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Therapeutic Area
15.6.4. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Geographical Region
15.6.4.1. Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Scale of Operation
15.6.4.2. Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Type of Biologic
15.6.4.3. Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Therapeutic Area
15.6.4.4. Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Scale of Operation
15.6.4.5. Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Type of Biologic
15.6.4.6. Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Therapeutic Area
15.6.4.7. Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
15.6.4.8. Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
15.6.4.9. Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
15.7. Biologics Fill / Finish Services Market for Vials, 2021-2030
15.7.1. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Scale of Operation
15.7.2. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Type of Biologic
15.7.3. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Therapeutic Area
15.7.4. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Geographical Region
15.7.4.1. Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Scale of Operation
15.7.4.2. Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Type of Biologic
15.7.4.3. Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Therapeutic Area
15.7.4.4. Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Scale of Operation
15.7.4.5. Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Type of Biologic
15.7.4.6. Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Therapeutic Area
15.7.4.7. Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
15.7.4.8. Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
15.7.4.9. Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
16. FUTURE GROWTH OPPORTUNITIES
16.1. Chapter Overview
16.2. Growing Biopharmaceutical Pipeline
16.3. Increase in Outsourcing of Fill / Finish Activities
16.4. Rising Focus on Self-Administration of Drugs
16.5. Advances in Aseptic Fill / Finish Technologies
16.6. Growing Opportunities in the Asia-Pacific Region
17. CASE STUDY: ROBOTIC SYSTEMS IN FILL / FINISH OPERATIONS
17.1. Chapter Overview
17.2. Contract Service Providers: List of Fill / Finish Equipment
17.3. Role of Robotic Systems in Fill / Finish Operations
17.3.1. Types of Robots Used in Pharmaceutical Operations
17.3.2. Key Considerations for Selecting a Robotic System
17.3.3. Advantages of Robotic Systems
17.3.4. Disadvantages of Robotic Systems
17.4. Companies Providing Robots for Use in the Pharmaceutical Industry
17.5. Companies Providing Isolator based Aseptic Filling Systems
17.6. Concluding Remarks
18. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL / FINISH
18.1. Chapter Overview
18.2. Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations
18.2.1. Advantages of Ready-to-Use Packaging Components
18.2.2. Disadvantages of Ready-to-Use Packaging Components
18.3. Companies Providing Ready-to-Use Packaging Components
18.4. Concluding Remarks
19. CONCLUDING REMARKS
20. INTERVIEW TRANSCRIPTS
20.1 Chapter Overview
20.2 IDT Biologika
20.2.1. Company Snapshot
20.2.1. Interview Transcript: Gregor Kawaletz, Chief Commercial Officer
20.3 Cytovance Biologics
20.3.1. Company Snapshot
20.3.2. Interview Transcript: Matt Delaney, Vice President of Business Development and Marketing
20.4. Syngene
20.4.1. Company Snapshot
20.4.2. Interview Transcript: Purushottam Singnurkar, Research Director and Head of Formulation Development
20.5 oncomed manufacturing
20.5.1. Company Snapshot
20.5.2. Interview Transcript: Ales Sima, Business Development Manager
20.6 Yposkesi
20.6.1. Company Snapshot
20.6.2. Interview Transcript: Amit, Technology Watch Manager
20.7 HALIX
20.7.1. Company Snapshot
20.7.2. Interview Transcript: Jos Vergeest, International Business Developer
21. APPENDIX 1: TABULATED DATA
22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Various Types of Biologics
Figure 3.2 Types of Third-Party Service Providers
Figure 3.3 Commonly Outsourced Operations
Figure 3.4 Steps Involved in Fill / Finish of Biologics
Figure 3.5 Key Considerations for Selecting a CMO Partner
Figure 3.6 Risks and Challenges of Outsourcing Biologics Fill / Finish Operations
Figure 4.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 4.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
Figure 4.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Figure 4.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 4.5 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging
Figure 4.6 Biologics Fill / Finish Service Providers: Distribution by Type of Biologic Involved and Type of Packaging Form
Figure 4.7 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Figure 4.8 Biologics Fill / Finish Service Providers: Distribution by Additional Services Offered
Figure 5.1 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers in North America
Figure 5.2 Company Competitiveness Analysis: Players Offering Services in Ampoules (North America)
Figure 5.3 Company Competitiveness Analysis: Players Offering Services in Cartridges (North America)
Figure 5.4 Company Competitiveness Analysis: Players Offering Services in Syringes (North America)
Figure 5.5 Company Competitiveness Analysis: Players Offering Services in Vials (North America)
Figure 5.6 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers in Europe
Figure 5.7 Company Competitiveness Analysis: Players Offering Services in Ampoules (Europe)
Figure 5.8 Company Competitiveness Analysis: Players Offering Services in Cartridges (Europe)
Figure 5.9 Company Competitiveness Analysis: Players Offering Services in Syringes (Europe)
Figure 5.10 Company Competitiveness Analysis: Players Offering Services in Vials (Europe)
Figure 5.11 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers in (Asia-Pacific and Rest of the World)
Figure 5.12 Company Competitiveness Analysis: Players Offering Services in Ampoules (Asia-Pacific and Rest of the World)
Figure 5.13 Company Competitiveness Analysis: Players Offering Services in Cartridges (Asia-Pacific and Rest of World)
Figure 5.14 Company Competitiveness Analysis: Players Offering Services in Syringes (Asia-Pacific and Rest of the World)
Figure 5.15 Company Competitiveness Analysis: Players Offering Services in Vials (Asia-Pacific and Rest of the World)
Figure 6.1 AbbVie Contract Manufacturing: Overview of Service Portfolio
Figure 6.2 AbbVie: Annual Revenues, 2015-2020 (USD Billion)
Figure 6.3 BioPharma Solutions: Overview of Service Portfolio
Figure 6.4 BioReliance: Overview of Service Portfolio
Figure 6.5 Merck KGaA: Annual Revenues, 2014 - 9M 2020 (EUR Billion)
Figure 6.6 Merck KGaA: Annual Revenues by Business Segmnent, 9M 2020 (EUR Billion)
Figure 6.7 Catalent Biologics: Overview of Service Portfolio
Figure 6.8 Catalent Biologics: Annual Revenues, 2015-2020 (USD Billion)
Figure 6.9 Patheon: Overview of Service Portfolio
Figure 6.10 Thermo Fisher Scientific: Annual Revenues, 2014-9M 2020 (USD Billion)
Figure 7.1 Boehringer Ingelheim BioXcellence: Overview of Service Portfolio
Figure 7.2 Boehringer Ingelheim BioXcellence: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Figure 7.3 Lonza: Overview of Service Portfolio
Figure 7.4 Lonza: Annual Revenues, 2014 - H1 2020 (CHF Million)
Figure 7.5 Pierre Fabre: Overview of Service Portfolio
Figure 7.6 Pierre Fabre: Annual Revenues, 2015 - 2019 (EUR Billion)
Figure 7.7 Recipharm: Overview of Service Portfolio
Figure 7.8 Recipharm: Annual Revenues, 2012 - 9M 2020 (SEK Billion)
Figure 7.9 Recipharm: Revenues by Business Divisions, 9M 2020 (SEK Billion)
Figure 7.10 Wacker Biotech: Overview of Service Portfolio
Figure 7.11 Wacker Chemie: Annual Revenues, 2015 - 2020 (EUR Billion)
Figure 8.1 Asymchem: Overview of Service Portfolio
Figure 8.2 Asymchem: Annual Revenues, 2015-2019 (USD Million)
Figure 8.3 ChemPartner: Overview of Service Portfolio
Figure 8.4 Samsung Biologics: Overview of Service Portfolio
Figure 8.5 Samsung Biologics: Annual Revenues, FY 2016 - FY 2020 (KRW Billion)
Figure 8.6 Syngene: Overview of Service Portfolio
Figure 8.7 Syngene: Annual Revenues, FY 2016 – Q3 FY 2021 (INR Million)
Figure 8.8 Takara Bio: Overview of Service Portfolio
Figure 8.9 Takara Bio: Annual Revenues, FY 2016 - H1 FY 2021 (JPY Billion)
Figure 8.10 WuXi Biologics: Overview of Service Portfolio
Figure 8.11 WuXi Biologics: Annual Revenues, 2014 - H1 2020 (RMB Million)
Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Service
Figure 9.5 Partnerships and Collaborations: Distribution by Types of Process
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Biologic Involved and Type of Service Offered
Figure 9.7 Partnerships and Collaborations: Most Active Players
Figure 9.8 Partnerships and Collaborations: Geographical Analysis
Figure 9.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.10 Partnerships and Collaborations: Distribution by Geographical Location of Facilities
Figure 10.1 Recent Expansions: Distribution by Year of Expansion, 2013-2021 (till January)
Figure 10.2 Recent Expansions: Distribution by Type of Expansion
Figure 10.3 Recent Expansions: Distribution by Type of Packaging Form
Figure 10.4 Recent Expansions: Distribution by Type of Expansion and Type of Service
Figure 10.5 Recent Expansions: Distribution by Type of Biologic Involved
Figure 10.6 Recent Expansions: Distribution by Type of Biologic Involved and Scale of Operation
Figure 10.7 Recent Expansions: Distribution by Geographical Location
Figure 10.8 Recent Expansions: Most Active Players
Figure 10.9 Recent Expansions: Distribution by Location of Expansion Project
Figure 10.10 Recent Expansions in North America: Distribution by Type of Service Offered and Type of Biologic Involved
Figure 10.11 Recent Expansions in Europe: Distribution by Type of Service and Type of Biologic
Figure 10.12 Recent Expansions in Asia-Pacific: Distribution by Type of Service and Type of Biologic
Figure 11.1 Capacity for Filling Ampoules: Distribution by Company Size (Sample Data Set)
Figure 11.2 Capacity for Filling Cartridges: Distribution by Company Size (Sample Data Set)
Figure 11.3 Capacity for Filling Syringes: Distribution by Company Size (Sample Data Set)
Figure 11.4 Capacity for Filling Vials: Distribution by Company Size (Sample Data Set)
Figure 11.5 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Type of Packaging (Million Units)
Figure 11.6 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Company Size (Million Units)
Figure 11.7 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Scale of Operation (Million Units)
Figure 11.8 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Headquarters (Million Units)
Figure 11.9 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Figure 11.10 Global Fill / Finish Capacity (by Fill Volume): Distribution by Type of Packaging (Kilo Liters)
Figure 11.11 Global Fill / Finish Capacity (by Fill Volume): Distribution by Company Size (Kilo Liters)
Figure 11.12 Global Fill / Finish Capacity (by Fill Volume): Distribution by Scale of Operation (Kilo Liters)
Figure 11.13 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Headquarters (Kilo Liters)
Figure 11.14 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Kilo Liters)
Figure 11.15 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Figure 11.16 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Range of Capacity by Company Size
Figure 11.17 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Figure 11.18 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Figure 11.19 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Figure 11.20 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Company Size (Liters)
Figure 11.21 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Range of Capacity by Company Size (Liters)
Figure 11.22 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Scale of Operation (Liters)
Figure 11.23 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Headquarters (Liters)
Figure 11.24 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.25 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Figure 11.26 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Range of Capacity by Company Size
Figure 11.27 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Figure 11.28 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Figure 11.29 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Figure 11.30 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Company Size (Liters)
Figure 11.31 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Range of Capacity by Company Size (Liters)
Figure 11.32 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Scale of Operation (Liters)
Figure 11.33 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Headquarters (Liters)
Figure 11.34 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.35 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Range of Capacity by Company Size (Thousand Units)
Figure 11.36 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Range of Capacity by Company Size (Thousand Units)
Figure 11.37 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Figure 11.38 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Figure 11.39 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Figure 11.40 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Company Size (Liters)
Figure 11.41 Global Fill / Finish Capacity for Syringes (by Fill Volume): Range of Capacity by Company Size (Liters)
Figure 11.42 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Scale of Operation (Liters)
Figure 11.43 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Headquarters (Liters)
Figure 11.44 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.45 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Figure 11.46 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Range of Capacity by Company Size
Figure 11.47 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Figure 11.48 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Figure 11.49 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Figure 11.50 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Company Size (Kilo Liters)
Figure 11.51 Global Fill / Finish Capacity for Vials (by Fill Volume): Range of Capacity by Company Size (Kilo Liters)
Figure 11.52 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Scale of Operation (Kilo Liters)
Figure 11.53 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Headquarters (Kilo Liters)
Figure 11.54 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 12.1 Global Demand for Biologics Fill / Finish Services (Million Liters)
Figure 12.2 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Packaging (Kilo Liters)
Figure 12.3 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Biologic Involved (Kilo Liters)
Figure 12.4 Global Demand for Biologics Fill / Finish Services: Distribution by Therapeutic Area (Kilo Liters)
Figure 12.5 Global Demand for Biologics Fill / Finish Services: Distribution by Geographical Location (Kilo Liters)
Figure 12.6 Global Biologics Fill / Finish Services: Demand and Supply, 2021-2030
Figure 13.1 Biologics Manufacturing and Fill / Finish: Key Performance Indicators (KPIs)
Figure 13.2 Financial Indicators: Comparative Analysis of KPIs Considered by Big Pharma Companies
Figure 13.3 Financial Indicators: Big Pharma Perspective
Figure 13.4 Financial Indicators: Contract Manufacturers’ Perspective
Figure 13.5 Process / Capability-related Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.6 Process / Capability-related Indicators: Big Pharma Perspective
Figure 13.7 Process / Capability-related Indicators: Contract Manufacturers’ Perspective
Figure 13.8 Market Reputation-related Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.9 Market Reputation-related Indicators: Big Pharma Perspective
Figure 13.10 Market Reputation-related Indicators: Contract Manufacturers’ Perspective
Figure 13.11 Other Performance Indicators: Contract Manufacturers’ Perspective
Figure 14.1 Regional Capability Assessment: Biologic Fill / Finish Capabilities in North America
Figure 14.2 Regional Capability Assessment: Biologic Fill / Finish Capabilities in Europe
Figure 14.3 Regional Capability Assessment: Biologic Fill / Finish Capabilities in Asia-Pacific and Rest of the World
Figure 14.4 Regional Capability Assessment: Comparison of Capabilities across Different Regions
Figure 15.1 Overall Biologics Fill / Finish Services Market, 2021-2030 (USD Billion)
Figure 15.2 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Packaging (USD Million)
Figure 15.3 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.4 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.5 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.6 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Geographical Region (USD Million)
Figure 15.7 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Countries (USD Million)
Figure 15.8 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Packaging (USD Million)
Figure 15.9 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.10 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.11 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.12 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Countries (USD Million)
Figure 15.13 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Packaging (USD Million)
Figure 15.14 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.15 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.16 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.17 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Countries (USD Million)
Figure 15.18 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Packaging (USD Million)
Figure 15.19 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.20 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.21 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.22 Biologics Fill / Finish Services Market for Ampoules, 2021-2030 (USD Million)
Figure 15.23 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.24 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.25 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.26 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Geographical Region (USD Million)
Figure 15.27 Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.28 Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.29 Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.30 Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.31 Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.32 Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.33 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.34 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.35 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.36 Biologics Fill / Finish Services Market for Cartridges, 2021-2030 (USD Million)
Figure 15.37 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.38 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.39 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.40 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Geographical Region (USD Million)
Figure 15.41 Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.42 Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.43 Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.44 Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.45 Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.46 Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.47 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.48 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.49 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.50 Biologics Fill / Finish Services Market for Syringes, 2021-2030 (USD Million)
Figure 15.51 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.52 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.53 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.54 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Geographical Region (USD Million)
Figure 15.55 Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.56 Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.57 Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.58 Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.59 Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.60 Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.61 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.62 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.63 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.64 Biologics Fill / Finish Services Market for Vials, 2021-2030 (USD Million)
Figure 15.65 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.66 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.67 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.68 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Geographical Region (USD Million)
Figure 15.69 Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.70 Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.71 Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.72 Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.73 Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.74 Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.75 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.76 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.77 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.1 Growth Opportunities for Biologics Fill / Finish Service Providers
Figure 16.2 New Molecular Entities Approved by the FDA, 2011-2020
Figure 17.1 Key Considerations for Selecting a Robotic System
Figure 17.2 Advantages of Robotic Systems in Pharmaceutical Operations
Figure 18.1 Key Drivers of Ready-to-Use Platform
Figure 19.1 Concluding Remarks: Current Biologic Fill / Finish Service Providers Market Landscape Summary
Figure 19.2 Concluding Remarks: Recent Partnerships
Figure 19.3 Concluding Remarks: Recent Expansions
Figure 19.4 Concluding Remarks: Capacity Analysis
Figure 19.5 Concluding Remarks: Demand Analysis
Figure 19.6 Concluding Remarks: Market Sizing and Opportunity Analysis for Biologic Fill / Finish Services Market  
LIST OF TABLES
Table 3.1 Best-Selling Drugs of 2019
Table 4.1 Biologics Fill / Finish Service Providers: List of Companies
Table 4.2 Biologics Fill / Finish Service Providers: Information on Type of Packaging
Table 4.3 Biologics Fill / Finish Service Providers: Information on Type of Biologic Involved
Table 4.4 Biologics Fill / Finish Service Providers: Information on Scale of Operation
Table 4.5 Biologics Fill / Finish Service Providers: Information on Additional Services Offered
Table 4.6 Biologics Fill / Finish Service Providers: Information on Fill / Finish Capacity
Table 6.1 Biologics Fill / Finish Service Providers in North America: List of Profiled Companies
Table 6.2 AbbVie Contract Manufacturing: Company Overview
Table 6.3 AbbVie Contract Manufacturing: Overview of Service Portfolio
Table 6.4 AbbVie Contract Manufacturing: Sterile Manufacturing Facilities
Table 6.5 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 6.6 BioPharma Solutions: Company Overview
Table 6.7 BioPharma Solutions: Overview of Service Portfolio
Table 6.8 BioPharma Solutions: Sterile Manufacturing Facilities
Table 6.9 BioPharma Solutions: Recent Developments and Future Outlook
Table 6.10 BioReliance: Company Overview
Table 6.11 BioReliance: Overview of Service Portfolio
Table 6.12 BioReliance: Sterile Manufacturing Facilities
Table 6.13 BioReliance: Recent Developments and Future Outlook
Table 6.14 Catalent Biologics: Company Overview
Table 6.15 Catalent Biologics: Overview of Service Portfolio
Table 6.16 Catalent Biologics: Sterile Manufacturing Facilities
Table 6.17 Catalent Biologics: Recent Developments and Future Outlook
Table 6.18 Patheon: Company Overview
Table 6.19 Patheon: Overview of Service Portfolio
Table 6.20 Patheon: Sterile Manufacturing Facilities
Table 6.21 Patheon: Recent Developments and Future Outlook
Table 7.1 Biologics Fill / Finish Service Providers in Europe: List of Profiled Companies
Table 7.2 Boehringer Ingelheim BioXcellence: Company Overview
Table 7.3 Boehringer Ingelheim BioXcellence: Overview of Service Portfolio
Table 7.4 Boehringer Ingelheim BioXcellence: Sterile Manufacturing Facilities
Table 7.5 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
Table 7.6 Lonza: Company Overview
Table 7.7 Lonza: Overview of Service Portfolio
Table 7.8 Lonza: Sterile Manufacturing Facilities
Table 7.9 Lonza: Recent Developments and Future Outlook
Table 7.10 Pierre Fabre: Company Overview
Table 7.11 Pierre Fabre: Overview of Service Portfolio
Table 7.12 Pierre Fabre: Sterile Manufacturing Facilities
Table 7.13 Pierre Fabre: Recent Developments and Future Outlook
Table 7.14 Recipharm: Company Overview
Table 7.15 Recipharm: Overview of Service Portfolio
Table 7.16 Recipharm: Sterile Manufacturing Facilities
Table 7.17 Recipharm: Recent Developments and Future Outlook
Table 7.18 Wacker Biotech: Company Overview
Table 7.19 Wacker Biotech: Overview of Service Portfolio
Table 7.20 Wacker Biotech: Sterile Manufacturing Facilities
Table 7.21 Wacker Biotech: Recent Developments and Future Outlook
Table 8.1 Biologics Fill / Finish Service Providers in Asia-Pacific: List of Profiled Companies
Table 8.2 Asymchem: Company Overview
Table 8.3 Asymchem: Overview of Service Portfolio
Table 8.4 Asymchem: Sterile Manufacturing Facilities
Table 8.5 Asymchem: Recent Developments and Future Outlook
Table 8.6 Syngene: Company Overview
Table 8.7 Syngene: Overview of Service Portfolio
Table 8.8 Syngene: Recent Developments and Future Outlook
Table 8.9 Takara Bio: Company Overview
Table 8.10 Takara Bio: Overview of Service Portfolio
Table 8.11 Takara Bio: Recent Developments and Future Outlook
Table 8.12 WuXi Biologics: Company Overview
Table 8.13 WuXi Biologics: Overview of Drug Product Services
Table 8.14 WuXi Biologics: Sterile Manufacturing Facilities
Table 8.15 WuXi Biologics: Recent Developments and Future Outlook
Table 9.1 Biologics Fill / Finish Service Providers: Partnerships and Collaborations, 2013-2020
Table 9.2 Partnerships and Collaborations: Information on Types of Services Offered, 2013-2020
Table 9.3 Partnerships and Collaborations: Information on Types of Biologics Involved, 2013-2020
Table 10.1 Biologics Fill / Finish Service Providers: Recent Expansions, 2013-2021 (till January)
Table 10.2 Recent Expansions, 2013-2021 (till January): Information on Type of Packaging
Table 10.3 Recent Expansions, 2013-2021 (till January): Information on Types of Services
Table 10.4 Recent Expansions, 2013-2021 (till January): Information on Types of Biologics
Table 11.1 Average Fill / Finish Capacity for Ampoules (Number of Units Filled) by Company Size (Sample Data Set)
Table 11.2 Average Fill / Finish Capacity for Cartridges (Number of Units Filled) by Company Size (Sample Data Set)
Table 11.3 Average Fill / Finish Capacity for Syringes (Number of Units Filled) by Company Size (Sample Data Set)
Table 11.4 Average Fill / Finish Capacity for Vials (Number of Units Filled) by Company Size (Sample Data Set)
Table 11.5 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Company Size
Table 11.6 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Company Size
Table 11.7 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Company Size
Table 11.8 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Company Size
Table 11.9 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Company Size
Table 11.10 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Company Size
Table 11.11 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Company Size
Table 11.12 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Company Size
Table 12.1 Global Biologics Fill / Finish Services: Annual Supply for Outsourcing, 2021-2030 (Million Liters)
Table 16.1 Patent Expiry of Biologics, 2021-2023
Table 17.1 Biologics Fill / Finish Service Providers: Information on Fill / Finish Equipment Used
Table 17.2 List of Pharmaceutical Robotics Manufacturers
Table 17.3 Isolator based Aseptic Filling Systems: Information on Compatible Primary Container
Table 18.1 List of Companies Supplying Ready-to-Use Packaging Components
Table 19.1 Biologics Fill / Finish Service Providers: Summary of the Report
Table 21.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Table 21.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
Table 21.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Table 21.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Table 21.5 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging
Table 21.6 Biologics Fill / Finish Service Providers: Distribution by Type of Biologic Involved and Type of Packaging Form
Table 21.7 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Table 21.8 Biologics Fill / Finish Service Providers: Distribution by Type of Additional Services Offered
Table 21.9 AbbVie: Annual Revenues, 2015 - 2020 (USD Billion)
Table 21.10 Merck KGaA: Annual Revenues, 2014 - 9M 2020 (EUR Billion)
Table 21.11 Merck KGaA: Annual Revenues by Business Segment, 9M 2020 (EUR Billion)
Table 21.12 Catalent Biologics: Annual Revenues, 2015 - 2020 (USD Billion)
Table 21.13 Thermo Fisher Scientific: Annual Revenues, 2014 - 9M 2020 (USD Billion)
Table 21.14 Patheon: Annual Revenues, 2012 - H1 2017 (USD Million)
Table 21.15 Boehringer Ingelheim BioXcellence: Overview of Service Portfolio
Table 21.16 Boehringer Ingelheim BioXcellence: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Table 21.17 Lonza: Annual Revenues, 2014 - H1 2020 (CHF Million)
Table 21.18 Pierre Fabre: Annual Revenues, 2015 - 2018 (EUR Billion)
Table 21.19 Recipharm: Annual Revenues, 2012 - 9M 2020 (SEK Billion)
Table 21.20 Recipharm: Revenues by Business Divisions, 9M 2020 (SEK Billion)
Table 21.21 Wacker Chemie: Annual Revenues, 2015 - 2020 (EUR Billion)
Table 21.22 Asymchem: Annual Revenues, 2015 - 2019 (USD Million)
Table 21.23 Samsung Biologics: Annual Revenues, FY 2016 - FY 2020 (KRW Billion)
Table 21.24 Syngene: Annual Revenues, FY 2016 - 9M FY 2021 (INR Million)
Table 21.25 Takara Bio: Annual Revenues, FY 2016 - H1 FY 2021 (JPY Billion)
Table 21.26 WuXi Biologics: Annual Revenues, 2014 - H1 2020 (RMB Million)
Table 21.27 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2020
Table 21.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.29 Partnerships and Collaborations: Distribution by Scale of Operation
Table 21.30 Partnerships and Collaborations: Distribution by Types of Services Offered
Table 21.31 Partnerships and Collaborations: Distribution by Types of Processes
Table 21.32 Partnerships and Collaborations: Distribution by Types of Biologics Involved and Type of Services Offered
Table 21.33 Partnerships and Collaborations: Most Active Players
Table 21.34 Partnerships and Collaborations: Geographical Analysis
Table 21.35 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 21.36 Partnerships and Collaborations: Distribution by Geographical Location of Facilities
Table 21.37 Recent Expansions: Distribution by Year of Expansion, 2013-2021 (till January)
Table 21.38 Recent Expansions: Distribution by Type of Expansion
Table 21.39 Recent Expansions: Distribution by Type of Packaging
Table 21.40 Recent Expansions: Distribution by Type of Expansion and Type of Service
Table 21.41 Recent Expansions: Distribution by Type of Biologic Involved
Table 21.42 Recent Expansions: Distribution by Type of Biologic and Scale of Operation
Table 21.43 Recent Expansions: Distribution by Geographical Location
Table 21.44 Recent Expansions: Distribution by Most Active Players
Table 21.45 Recent Expansions: Distribution by Location of Expansion Project
Table 21.46 Recent Expansions in North America: Distribution by Type of Service Offered and Type of Biologic Involved
Table 21.47 Recent Expansions in Europe: Distribution by Type of Service and Type of Biologic
Table 21.48 Recent Expansions in Asia-Pacific: Distribution by Type of Service and Type of Biologic
Table 21.49 Capacity for Filling Ampoules: Distribution by Company Size (Sample Data Set)
Table 21.50 Capacity for Filling Cartridges: Distribution by Company Size (Sample Data Set)
Table 21.51 Capacity for Filling Syringes: Distribution by Company Size (Sample Data Set)
Table 21.52 Capacity for Filling Vials: Distribution by Company Size (Sample Data Set)
Table 21.53 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Type of Packaging (Million Units)
Table 21.54 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Company Size (Million Units)
Table 21.55 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Scale of Operation (Million Units)
Table 21.56 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Headquarters (Million Units)
Table 21.57 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Table 21.58 Global Fill / Finish Capacity (by Fill Volume): Distribution by Type of Packaging (Kilo Liters)
Table 21.59 Global Fill / Finish Capacity (by Fill Volume): Distribution by Company Size (Kilo Liters)
Table 21.60 Global Fill / Finish Capacity (by Fill Volume): Distribution by Scale of Operation (Kilo Liters)
Table 21.61 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Headquarters (Kilo Liters)
Table 21.62 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Kilo Liters)
Table 21.63 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Table 21.64 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Table 21.65 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Table 21.66 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Table 21.67 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Company Size (Liters)
Table 21.68 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Scale of Operation (Liters)
Table 21.69 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Headquarters (Liters)
Table 21.70 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 21.71 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Table 21.72 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Table 21.73 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Table 21.74 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Table 21.75 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Company Size (Liters)
Table 21.76 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Scale of Operation (Liters)
Table 21.77 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Headquarters (Liters)
Table 21.78 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 21.79 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Company Size
Table 21.80 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Table 21.81 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Table 21.82 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Table 21.83 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Company Size (Liters)
Table 21.84 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Scale of Operation (Liters)
Table 21.85 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Headquarters (Liters)
Table 21.86 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 21.87 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Table 21.88 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Table 21.89 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Table 21.90 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Table 21.91 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Company Size (Liters)
Table 21.92 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Scale of Operation (Liters)
Table 21.93 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Headquarters (Liters)
Table 21.94 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 21.95 Global Demand for Biologics Fill / Finish Services (Million Liters)
Table 21.96 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Packaging (Kilo Liters)
Table 21.97 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Biologic (Kilo Liters)
Table 21.98 Global Demand for Biologics Fill / Finish Services: Distribution by Therapeutic Area (Kilo Liters)
Table 21.99 Global Demand for Biologics Fill / Finish Services: Distribution by Geographical Location (Kilo Liters)
Table 21.100 Global Biologics Fill / Finish Services: Demand and Supply, 2021-2030
Table 21.101 Overall Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 21.102 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
Table 21.103 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.104 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.105 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.106 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
Table 21.107 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Countries (USD Million)
Table 21.108 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
Table 21.109 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.110 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.111 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.112 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Countries (USD Million)
Table 21.113 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
Table 21.114 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.115 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.116 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.117 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Countries (USD Million)
Table 21.118 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
Table 21.119 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.120 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.121 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.122 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
Table 21.123 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.124 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.125 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.126 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
Table 21.127 Biologics Fill / Finish Services Market for Ampoules in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.128 Biologics Fill / Finish Services Market for Ampoules in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.129 Biologics Fill / Finish Services Market for Ampoules in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.130 Biologics Fill / Finish Services Market for Ampoules in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.131 Biologics Fill / Finish Services Market for Ampoules in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.132 Biologics Fill / Finish Services Market for Ampoules in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.133 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.134 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.135 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.136 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
Table 21.137 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.138 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.139 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.140 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
Table 21.141 Biologics Fill / Finish Services Market for Cartridges in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.142 Biologics Fill / Finish Services Market for Cartridges in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.143 Biologics Fill / Finish Services Market for Cartridges in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.144 Biologics Fill / Finish Services Market for Cartridges in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.145 Biologics Fill / Finish Services Market for Cartridges in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.146 Biologics Fill / Finish Services Market for Cartridges in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.147 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.148 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.149 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.150 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
Table 21.151 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.152 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.153 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.154 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
Table 21.155 Biologics Fill / Finish Services Market for Syringes in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.156 Biologics Fill / Finish Services Market for Syringes in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.157 Biologics Fill / Finish Services Market for Syringes in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.158 Biologics Fill / Finish Services Market for Syringes in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.159 Biologics Fill / Finish Services Market for Syringes in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.160 Biologics Fill / Finish Services Market for Syringes in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.161 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.162 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.163 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.164 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
Table 21.165 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.166 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.167 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.168 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
Table 21.169 Biologics Fill / Finish Services Market for Vials in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.170 Biologics Fill / Finish Services Market for Vials in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.171 Biologics Fill / Finish Services Market for Vials in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.172 Biologics Fill / Finish Services Market for Vials in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.173 Biologics Fill / Finish Services Market for Vials in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.174 Biologics Fill / Finish Services Market for Vials in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.175 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.176 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.177 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.178 New Molecular Entities Approved by the FDA, 2011-2020

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook